Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827359 · ClinicalTrials.gov registry record · Phase 2
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00827359 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00827359, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-03 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827359
The ClinicalTrials.gov registry entry for NCT00827359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT00827359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827359 about?
NCT00827359 is a clinical study titled "Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma". The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
What is the current status of trial NCT00827359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-03. Estimated completion is 2018-06.
What interventions are being tested in trial NCT00827359?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT00827359?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.